Business Wire

Physicians’ Education Resource® Hosts the 38th Annual Miami Breast Cancer Conference® in Expanded, Interactive Virtual Meeting Format

24.2.2021 21:12:00 EET | Business Wire | Press release

Share

As the leading go-to resource for continuing medical education (CME), Physicians’ Education Resource®, LLC, (PER®), has been committed to improving the care for patients with breast cancer by educating the treatment team for nearly four decades. This commitment is more than professional, but also deeply personal. This annual marquee CME conference has been family-led since the beginning and continues to incorporate that family spirit into 2021 in the virtual setting.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224005893/en/

Traditionally hosted as a live marquee meeting, this year’s 38th Annual Miami Breast Cancer Conference® has transformed into a live-broadcast virtual and interactive experience leveraging new online meeting technologies. This year, the conference is more than Miami, and will bring the educational experience directly to health care professionals online.

For 37 years, the historic multidisciplinary Miami Breast Cancer Conference® has been a family-led annual meeting. By combining the conference’s legacy with the Hennessy family spirit and commitment infused into the DNA of MJH Life Sciences™, the parent company of PER®, this year’s meeting will continue to focus on improving the care of patients with breast cancer. The annual conference has become a landmark meeting that serves as the go-to resource for health care professionals to learn about the most important advancements in breast cancer treatment and how to translate these into clinical care.

“In its 38th year, whether this is your first time or your 31st time attending, PER® welcomes you as part of the Miami Breast Cancer Conference® family,” said Phil Talamo, CHCP, president of PER®. “Our community is full of dedicated oncologists, surgeons, pathologists, nurses, and more who are committed to elevating patient care. We know that it takes more than a team to treat breast cancer – it takes a family. During this year’s conference, we will virtually come together with a shared purpose of driving contemporary patient care using strategies that you hear on Friday and use on Monday.”

This year’s 38th Annual Miami Breast Cancer Conference® will continue this tradition increase the use innovative virtual technology to deliver the robust educational programming and top-notch presentations for which this conference is known for. New in 2021, PER® has expanded its afternoon programming to the full healthcare team with additional tracks on pathology, radiation oncology, and oncology nursing. To accommodate its international learners in European time zones, an international track will also be offered. This will broaden the Conference’s impact and bring vital members of the treatment team into the Miami Breast Cancer Conference family, united in the approach to improve the care of patients with breast cancer.

Additionally, this year’s expanded virtual program will feature world-class tumor board panels, multidisciplinary meet-the-expert sessions, case discussions, poster sessions, a video surgical library, lively Medical Crossfire® exchanges, and more. Included among the many important clinical and practical topics on the agenda are novel therapeutic targets, contemporary management issues, oncology care in the COVID-19 era, practical application of genomics, precision medicine, and more.

For more information and to register, click here.

About Physicians’ Education Resource® (PER®)

Since 1995, PER® has been dedicated to advancing cancer care through professional education and now advances patient care and treatment strategies on a wide variety of chronic illnesses and diseases. In 2016, PER® initiated continuing medical education (CME) programming in the cardiovascular and endocrinology areas. Although it is expanding into topics outside of oncology, PER® stands as the leading provider of live, online and print CME activities related to oncology and hematology. The high-quality, evidence-based activities feature leading distinguished experts who focus on the application of practice-changing advances. PER® is accredited by the Accreditation Council for Continuing Medical Education and the California Board of Registered Nursing. PER® is a brand of MJH Life Sciences™, the largest privately held, independent, full-service medical media company in North America dedicated to delivering trusted health care news across multiple channels.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PER® Media Contact
Alexandra Ventura, 609-716-7777
aventura@mjhlifesciences.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations30.4.2026 15:05:00 EEST | Press release

Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/ David Weinreich, Global Head of R&D and Chief Medical Officer “People living with lupus continue to face significant challenges in achieving disease control and are very often affected by itchy, painful and stigmatized skin manifestations,” said David Weinreich, Global Head of R&D, Merck. “With enpatoran, we aim to target the underlying drivers of lupus and redefine how to approach the disease by understanding both visible skin manifestations and systemic activity.” Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor designed to modulate pathways central to lupus-related inflammatio

The LYCRA Company Strengthens Sustainability Leadership, Appoints Alistair Williamson as VP of Product Sustainability30.4.2026 15:00:00 EEST | Press release

The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. In this role, he will guide the company’s next chapter of sustainability strategy and oversee all initiatives aimed at reducing environmental impact across products, operations, and innovation platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430942396/en/ The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. Williamson has four decades of experience in textile fibers and apparel, having held commercial, sales, and marketing leadership roles across EMEA, North America, and South Asia. Before joining the predecessor of The LYCRA Company i

Riskified Announces 2026 Titans of Ecommerce Award Winners30.4.2026 15:00:00 EEST | Press release

Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today announced the 2026 Titans of Ecommerce Awards, recognizing outstanding ecommerce leaders who are redefining fraud prevention while driving business growth. The winners are: Titan of Americas: Joseph Chin, Senior Director of Revenue Assurance, Michael Kors Joseph Chin has evolved revenue assurance into a strategic lever for growth at Michael Kors. Deeply knowledgeable in fraud and payments, he maintains a hands-on approach, continually collaborating with Riskified to identify innovative opportunities, optimize performance, and pilot new initiatives. Joseph is highly effective at building internal alignment and securing stakeholder buy-in for new strategies. His leadership shone during Cyber Five, where his close collaboration with Riskified and real-time insights delivered one of Michael Kors’ strongest performance periods. Titan of Europe: Ash Cummings, Ecommerce Fraud Prevention Manager, Gymshark A

CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 14:00:00 EEST | Press release

CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which was confirmed by the study’s independent DSMB (Data and Safety Monit

Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint ® and BluePrint ® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 14:00:00 EEST | Press release

Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors – a group that typically has favorable outcomes. MammaPrint (MP) identified a High Risk 2 (H2) subset, representing 10% of all patients and 5% of those

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye